Mark Mirochnick - Concepedia

Author

Mark Mirochnick

Also Known As

Helen Mcilleron, Jean-Philippe, Patrick, Lyerly, Anne D., M H Mirochnick, M Mirochnick, M. Mirochnick, MARK MIROCHNICK, Mark H Mirochnick, Mark H. Mirochnick, Mark Mirochnick

120

Publications

6.6K

Citations

H-Index

Concepts

All Affiliations

Boston University University of California San Diego Eunice Kennedy Shriver National Institute of Child Health and Human Development University of Southern California Harvard University

About

Mark Mirochnick is an author at Boston University specializing in medicine, pediatrics, and maternal health.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	20	22	3.2K
2	Public Health	9	9	400
3	Health Sciences	1	1	59
4	Emergency Medicine	1	1	75
5	Epidemiology	1	1	45

Mark Mirochnick

Publications

6.1K

Citations

H-Index

Page 1

	Year	Citations
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial Laura Guay, Philippa Musoke, Thomas R. Fleming, The Lancet ContraceptionNeonatal Single-dose NevirapineTreatment And PreventionPediatricsMaternal Health	1999	1.6K
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial J. Brooks Jackson, Philippa Musoke, Thomas R. Fleming, The Lancet ContraceptionNeonatal Single-dose NevirapineHivnet 012Treatment And Prevention18-Month Follow-up	2003	523
Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012) Susan H. Eshleman, Martin Mracna, Laura Guay, AIDS	2001	420
Three Postpartum Antiretroviral Regimens to Prevent Intrapartum HIV Infection Karin Nielsen‐Saines, D. Heather Watts, Valdiléa G. Veloso, New England Journal of Medicine	2012	230
A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006) Philippa Musoke, Laura Guay, Danstan Bagenda, AIDS	1999	215
Reduced lopinavir exposure during pregnancy Alice Stek, Mark Mirochnick, Edmund V. Capparelli, AIDS	2006	176
Late Dose-Response Effects of Prenatal Cocaine Exposure on Newborn Neurobehavioral Performance Edward Z. Tronick, Deborah A. Frank, Howard Cabral, PEDIATRICS	1996	153
Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial Shahin Lockman, Sean S. Brummel, Lauren Ziemba, The Lancet Treatment And PreventionAntiviral Drug DevelopmentAntiviral TherapyGynecologyMaternal Health	2021	152
Phase I evaluation of zidovudine administered to infants exposed at birth to the human immunodeficiency virus François D. Boucher, John F. Modlin, S Weller, The Journal of Pediatrics Maternal ImmunizationPediatricsNewborn MedicineHivHuman Immunodeficiency Virus	1993	112
Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV Nikki Mulligan, Brookie M. Best, Jiajia Wang, AIDS	2018	99

Page 1